Tuffaha H, Andronis L, Scuffham P. Setting Medical Research Future Fund Priorities: Assessing the Value of Research. Medical Journal of Australia 2016. In press.
Bluebelle Study Group (Andronis L, Blazeby J, Blencowe N, Calvert M, Coast J, Draycott T. et al.) The Bluebelle study (Phase A): A mixed-methods feasibility study to inform an RCT of surgical wound dressing strategies. BMJ Open 2016. In press.
Andronis L, Kinghorn P, Qiao S, Whitehurst D, Durrell S, McLeod H. Cost-Effectiveness of Non-Invasive and Non-Pharmacological Interventions for Low Back Pain: a Systematic Literature Review. Applied Health Economics and Health Policy 2016 (doi: 10.1007/s40258-016-0268-8). In press.
Bluebelle Study Group. Feasibility work to inform the design of a randomized clinical trial of wound dressings in elective and unplanned abdominal surgery. British Journal of Surgery 2016: doi 10.1002/bjs.10274. In press.
Andronis L, Goranitis I, Pirrie S, Pope A et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial. British Journal of Urology International 2016; 10.1111/bju.13549. In press.
Blazeby J and Bluebelle Study Group. Do dressings prevent infection of closed primary wounds after surgery? British Medical Journal 2016;353:i2270 doi: 10.1136/bmj.i2270. In press.
Duarte R, Lambe T, Raphael J, Eldabe S, Andronis L. Intrathecal drug delivery systems for the management of chronic non-cancer pain: protocol for a systematic review of economic evaluations. BMJ Open 2016; doi:10.1136/bmjopen-2016-012285. In press
James N, Pirrie S, Pope A, Barton D, Andronis L et al. TRAPEZE: A randomised controlled trial of the clinical and cost effectiveness of chemotherapy with zoledronic acid, strontium-89 or both, in men with bony metastatic castrate refractory prostate cancer. Health Technology Assessment 2016; 20(53):1-85.
Duarte R, Andronis L, Lenders M, de Vos C. Quality of life in patients with painful diabetic neuropathy following treatment with spinal cord stimulation. Quality of Life Research 2016 ; 25(7): 1771–1777.
Popplewell M, Deeks J, Andronis L, Roberts T, Bradbury A. Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. Trials 2015 DOI: 10.1186/s13063-015-1114-2. In press
James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel with strontium-89, zoledronic acid, neither, or both. JAMA Oncology 2016. 312-464-JAMA.
Andronis L, Barton P. Adjusting estimates of the expected value of information for implementation: theoretical framework and practical application. Medical Decision Making 2016 Apr;36(3): 296-307.
Andronis L, Barton P. Adjusting Expected Value of Sample Information Using Realistic Expectations around Implementation. Medical Decision Making 2016 Apr;36(3):284.
Andronis L, Billingham, L, Bryan S, Barton P. A practical application of value of information and prospective payback of research to prioritise evaluative research. Medical Decision Making 2016 Apr;36(3):321-34.
Thorn J, Coast J, Andronis L. Interpretation of the expected value of perfect information and research recommendations: a systematic review. Medical Decision Making 2016 Apr;36(3):285-95.
Andronis L. Analytic approaches for research priority-setting: issues, challenges and the way forward. Expert Review of Pharmacoeconomics and Outcomes Research 2015 Oct;15(5):745-54.
Mantopoulos T, Mitchell P, Welton N, McManus R, Andronis L. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. European Journal of Health Economics 2015. DOI: 10.1007/s10198-015-0731-8.
James N, Andronis L, Goranitis I, Pirrie S, Pope A, Barton D et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. J Clin Oncol 33 (suppl; abstr e16108), 2015
Brealey S, Andronis L, Dale V, Gibbon A, Gilbert F and Hendry M. The effect of waiting times from General Practitioner referral to Magnetic Resonance Imaging or orthopaedic consultation for the knee on patient-based outcomes. British Journal of Radiology 2012; 85 (1019): e1134-e1139
Bryan S, Dormandy E, Roberts T, Ades A, Barton P, Juarez-Garcia A, Andronis L, Karnon J and Marteau T. Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. British Journal of General Practice 2011; 61(591):620-627
Barton P, Andronis L, Briggs A, McPherson K and Capewell S. Effectiveness and cost-effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal 2011; 28: 343
Ashfaq K, Yahaya I , Hyde C, Andronis L, Barton P, Bayliss S et al. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technology Assessment 2010;14(54):iii-xi, 1.
Brealey S, Andronis L, Dennis L, Atwell C, Bryan S, Coulton S et al. Participants' preference for type of leaflet used to feed back the results of a randomised trial: a survey. Trials 2010; 11:16.
Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, Andronis L et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technology Assessment 2010; 14(50):1-103.
Bryan S, Andronis L, Hyde C, Connock M, Fry-Smith A and Wang D. Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technology Assessment 2010 May; 14 Suppl 1:9-15.
Hyde C, Bryan S, Juarez-Garcia A, Andronis L and Fry-Smith A. Infliximab for the treatment of ulcerative colitis. Health Technology Assessment 2009 Oct;13 Suppl 3:7-11.
Andronis L, Barton P and Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technology Assessment 2009 Jun;13(29):iii, ix-61.
DAMASK Trial Team (Brealey S, Andronis L, Atwell C, Bryan S, Collins S, Coulton S et al.)Effectiveness of GP access to MRI of the knee: a randomised trial. British Journal of General Practice 2008; 58(556): e1-8
DAMASK Trial Team (Andronis L, Brealey S, Atwell C, Bryan S, Collins S, Coulton S et al.) Cost effectiveness of magnetic resonance imaging of the knee for patients presenting in primary care. British Journal of General Practice 2008; 58(556): e10-16.
Published reports to the National Institute for Health and Clinical Excellence (NICE)
Andronis L, Barton P, Bayliss S and Hyde C. Prevention of cardiovascular disease. A systematic review of existing cost-effectiveness evidence. Report for the NICE Centre for Public Health Excellence. Available from: (Link)
Andronis L, Malottki K, Moore D and Barton P. Providing public health information to prevent skin cancer. Modelling strategies for primary prevention of skin cancer. Report for the NICE Centre for Public Health Excellence. Available from: (Link)
Malottki K, Wang D, Andronis L, Barton P, Fry-Smith A, Greenheld W, Pennant M and Moore D. Providing public health information to prevent skin cancer. Review of effectiveness and cost-effectiveness. Report for the NICE Centre for Public Health Excellence.Available from: (Link)